FGEN FibroGen Inc

47.39
+0.25  (+1%)
Previous Close 47.14
Open 47.49
Price To Book 6.96
Market Cap 4,134,780,533
Shares 87,250,064
Volume 578,160
Short Ratio
Av. Daily Volume 809,099
Stock charts supplied by TradingView

NewsSee all news

  1. FibroGen Announces Roxadustat Inclusion in China's National Reimbursement Drug List

    SAN FRANCISCO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today reported roxadustat has been included on the updated National Reimbursement Drug List (NRDL) released by China's National Healthcare

  2. HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors to Contact Its Attorneys, Firm Investigating Possible Securities Fraud

    SAN FRANCISCO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Hagens Berman urges FibroGen, Inc. (NASDAQ:FGEN) investors who have suffered significant losses to submit their loss now to learn if they qualify to recover their

  3. Glancy Prongay & Murray LLP Announces Investigation on Behalf of FibroGen, Inc. Investors

    Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) investors concerning the Company and its officers' possible violations of federal securities laws.

  4. INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of FibroGen, Inc. Investors

    Law Offices of Howard G. Smith announces an investigation on behalf of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) investors concerning the Company and its officers' possible violations of federal securities laws.

  5. FibroGen Reports Third Quarter 2019 Financial Results

    Roxadustat Positive Pooled Phase 3 Efficacy and Cardiovascular Safety Data Presented Last Friday at American Society of Nephrology 2019 Kidney WeekPlan to Submit Roxadustat U.S. NDA This Quarter Conference Call Today at

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

NDA filing due 4Q 2019.
Roxadustat
Anaemia in Chronic Kidney Disease
Phase 3 data due 2H 2020.
Roxadustat
Myelodysplastic syndromes (MDS)
Phase 2 detailed data due 2H 2019.
FG-3019
Duchenne muscular dystrophy
Phase 2 ongoing in Hong Kong. Future development uncertain
FG-3019
Liver fibrosis
Phase 3 trial initiation announced July 22, 2019.
Pamrevlumab (FG-3019) - ZEPHYRUS
Idiopathic pulmonary fibrosis
Phase 3 initiation of dosing announced October 23, 2019.
Pamrevlumab (FG-3019)
Pancreatic cancer
Phase 2 trial initiation announced September 26, 2019.
Roxadustat
Chemotherapy-induced anemia (CIA)

Latest News

  1. FibroGen Announces Roxadustat Inclusion in China's National Reimbursement Drug List

    SAN FRANCISCO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today reported roxadustat has been included on the updated National Reimbursement Drug List (NRDL) released by China's National Healthcare

  2. HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors to Contact Its Attorneys, Firm Investigating Possible Securities Fraud

    SAN FRANCISCO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Hagens Berman urges FibroGen, Inc. (NASDAQ:FGEN) investors who have suffered significant losses to submit their loss now to learn if they qualify to recover their

  3. Glancy Prongay & Murray LLP Announces Investigation on Behalf of FibroGen, Inc. Investors

    Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) investors concerning the Company and its officers' possible violations of federal securities laws.

  4. INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of FibroGen, Inc. Investors

    Law Offices of Howard G. Smith announces an investigation on behalf of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) investors concerning the Company and its officers' possible violations of federal securities laws.

  5. FibroGen Reports Third Quarter 2019 Financial Results

    Roxadustat Positive Pooled Phase 3 Efficacy and Cardiovascular Safety Data Presented Last Friday at American Society of Nephrology 2019 Kidney WeekPlan to Submit Roxadustat U.S. NDA This Quarter Conference Call Today at

  6. FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease

    Roxadustat cardiovascular safety comparable to placebo in non-dialysis dependent (NDD) patients, as assessed by Major Adverse Cardiovascular Events (MACE) and MACE+ Roxadustat did not increase risk of MACE and reduced

  7. FibroGen Presents Phase 3 Efficacy and Safety Results for Roxadustat Versus Epoetin Alfa as Treatment of Anemia in Incident Dialysis Patients with Chronic Kidney Disease

    WASHINGTON, Nov. 07, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), today announced results from the Phase 3 HIMALAYAS trial evaluating roxadustat for the treatment of anemia in incident dialysis (ID) patients

  8. HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors to Contact Its Attorneys Now, Firm Investigating Possible Securities Fraud

    SAN FRANCISCO, Nov. 5, 2019 /PRNewswire/ -- Hagens Berman urges FibroGen, Inc. (NASDAQ:FGEN) investors who have suffered significant losses to submit their loss now to learn if they qualify to recover their investment

  9. FibroGen, Inc. Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

    BOSTON, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors and whistleblowers nationwide, is investigating FibroGen, Inc. (NASDAQ:FGEN) and

  10. FibroGen To Report Third Quarter 2019 Financial Results on Monday, November 11, 2019

    SAN FRANCISCO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), today announced that financial results for the third quarter 2019 will be released after market on Monday, November 11, 2019. An investor

  11. FibroGen Announces First Patient Dosed in LAPIS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients With Locally Advanced Pancreatic Cancer

    SAN FRANCISCO, Oct. 23, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), today announced the dosing of the first patient in the LAPIS Phase 3 clinical study of pamrevlumab in patients with unresectable locally

  12. Roxadustat Global Phase 3 Results for Treatment of Chronic Kidney Disease (CKD) Anemia to be Presented at American Society of Nephrology Kidney Week 2019

    SAN FRANCISCO, Oct. 11, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), today announced that results from the global Phase 3 roxadustat clinical program will be presented at the American Society of Nephrology

  13. FibroGen Congratulates Dr. William G. Kaelin, Jr., Scientific Advisory Board Member, on Receipt of the 2019 Nobel Prize in Physiology or Medicine

    SAN FRANCISCO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) is pleased to announce that William G. Kaelin, Jr., who serves on the company's Scientific Advisory Board, has been awarded the 2019 Nobel

  14. FibroGen Receives One of China Pharmaceutical Industry's Highest Awards for Clinical Innovation for Roxadustat

    SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that roxadustat received the 2019 Dushu Lake Prize 独墅湖杯in China for "On-Market Innovative Drug with Highest Clinical

  15. FibroGen Announces Publication in the Lancet Respiratory Medicine of Positive Pamrevlumab Efficacy and Safety Data for the Praise Phase 2 Study in Idiopathic Pulmonary Fibrosis

    -- Novel Human Antibody Targets CTGF, A Central Mediator in Fibrosis -- SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced publication in The Lancet Respiratory Medicine of

  16. FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment of Anemia in Cancer Patients Receiving Chemotherapy

    SAN FRANCISCO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced first patient dosed in the company's Phase 2 clinical study of roxadustat, a first-in-class hypoxia-inducible factor prolyl

  17. Roxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients

    SAN FRANCISCO and TOKYO, Sept. 20, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN, Interim CEO: James A. Schoeneck, "FibroGen")) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.,

  18. Evrenzo® (roxadustat) Tablets Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients

    TOKYO and SAN FRANCISCO, Sept. 20, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (NASDAQ:FGEN, Interim CEO: James A Schoeneck.,

  19. Fibrogen Announces Passing of CEO Thomas B. Neff, Scientific Innovator and Pioneering Biopharmaceutical Executive

    SAN FRANCISCO, Aug. 26, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) announced today that Thomas B. Neff, Chief Executive Officer and Chairman of the Board of Directors of FibroGen, passed away unexpectedly